Constenla Dagna, Armien Blas, Arredondo Juan, Carabali Mabel, Carrasquilla Gabriel, Castro Raul, Durand Laure, Durán-Arenas Luis, García Maria Elena, Gallegos Rivera Verónica, Gontes Maria Luisa, López Juan Guillermo, McFarlane Charlton, Montoya Romeo, Sartori Ana Maria, Siqueira João Bosco, Martelli Celina Turchi
Department of International Health, Johns Hopkins Bloomberg School of Public Health (JHSPH), Baltimore, MD, USA; International Vaccines Institute, Dengue Vaccine Initiative (DVI), Seoul, Korea.
Gorgas Memorial Institute for Health Studies (GMI), Panama City, Panama.
Value Health Reg Issues. 2015 Dec;8:80-91. doi: 10.1016/j.vhri.2015.06.001. Epub 2015 Jul 28.
The overall aim of this article was to present a step-by-step guideline for determining the costs associated with dengue in dengue-endemic countries of the Latin American and the Caribbean region and to illustrate how each of these steps can be applied in dengue costing studies.
An expert panel was convened to develop standards for costing dengue so that over the next decade, decision makers will have access to improved information on the true cost of dengue in endemic countries of the Latin American and the Caribbean region. We described the outcome of the expert panel meeting, which resulted in the provision of a step-by-step dengue costing guideline that aims to provide direction to planners and program managers on how to estimate dengue economic burden studies, and provide a discussion forum of the methods used to cost dengue fever cases and outbreaks in a manner that should be accessible to persons with some familiarity with a cost study.
The guideline includes nine sequential steps: 1) definition of the scope of the study; 2) identification of the target population; 3) description of the study perspective; 4) definition of the time horizon; 5) calculation of the sample size; 6) definition of the unit of analysis; 7) identification of the cost items; 8) measurement and valuation of the cost items; and 9) handling of uncertainty. The trade-off between accurate, patient-level cost estimates and data availability constraints is discussed.
The current guideline is the result of constructive collaboration among a multidisciplinary research team to better ascertain the true economic burden of dengue across countries of the region.
本文的总体目标是为拉丁美洲和加勒比地区登革热流行国家确定登革热相关成本提供一份循序渐进的指南，并说明这些步骤中的每一步如何应用于登革热成本核算研究。
召集了一个专家小组来制定登革热成本核算标准，以便在未来十年，决策者能够获取有关拉丁美洲和加勒比地区流行国家登革热真实成本的更好信息。我们描述了专家小组会议的结果，该会议产生了一份循序渐进的登革热成本核算指南，旨在为规划者和项目管理者提供如何估计登革热经济负担研究的指导，并为以某种程度熟悉成本研究的人员能够理解的方式对登革热病例和疫情进行成本核算所使用的方法提供一个讨论论坛。
该指南包括九个连续步骤：1）研究范围的定义；2）目标人群识别；3）研究视角描述；（4）时间范围定义；5）样本量计算；6）分析单位定义；7）成本项目识别；8）成本项目的计量与估值；9）不确定性处理。讨论了准确的患者层面成本估计与数据可用性限制之间的权衡。
当前指南是多学科研究团队建设性合作的结果，以更好地确定该地区各国登革热的真实经济负担。
